Blockchain Registration Transaction Record

Lixte Expands Cancer Trial with MD Anderson, GSK to Double Enrollment

Lixte Biotechnology expands ovarian cancer trial with MD Anderson & GSK, doubling enrollment to 42 patients. Data expected 2026 for LB-100 + Dostarlimab combination therapy.

This development represents a significant advancement in cancer treatment research, particularly for ovarian clear cell cancer—a challenging subtype with limited therapeutic options. The expansion to Northwestern University's Robert H. Lurie Comprehensive Cancer Center not only accelerates patient enrollment but also brings additional expertise to the trial, potentially strengthening the study's findings. For patients with this specific cancer type and their families, this trial offers hope for more effective treatment combinations. More broadly, Lixte's approach targeting PP2A inhibition represents a novel mechanism in cancer therapy that could potentially benefit multiple cancer types beyond ovarian cancer. The collaboration between a biotech company, a leading cancer center, and a major pharmaceutical company demonstrates how partnerships can accelerate clinical development, potentially bringing new treatments to patients faster. Success in this trial could validate Lixte's activation lethality approach and open doors for similar combination therapies across oncology.